PR Newswire - Antengene To Present One Oral and Four Abstracts a...
Oral Presentation:a Phase II study of ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in patients with cervical cancer Three Poster presentations: Phase I/II studi...
Read More

ภาษาไทย
English